Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

NMR-based screening in drug discovery

Hajduk, Philip J., Meadows, Robert P., Fesik, Stephen W.·1999·Quarterly Reviews of Biophysics

Abstract

1. Introduction 211 2. Screening methods 213 2.1 Chemical shifts 213 2.2 Diffusion 214 2.3 Transverse relaxation 218 2.4 Nuclear Overhauser effects 218 3. Strategies for drug discovery and design 221 3.1 Fragment-based methods 221 3.1.1 Linked-fragment approach 221 3.1.2 Directed combinatorial libraries 222 3.1.3 Modification of high-affinity ligands 223 3.1.4 Solvent mapping techniques 223 3.2 High-throughput NMR-based screening 224 3.3 Enzymatic assays 226 4. Discovery of novel ligands 227 4.1 High-affinity ligands for FKBP 227 4.2 Potent inhibitors of stromelysin 229 4.3 Ligands for the DNA-binding domain of the E2 protein 233 4.4 Discovery of Erm methyltransferase inhibitors 233 4.5 Phosphotyrosine mimetics for SH2 domains 236 5. Conclusions 237 6. References 237 A critical step in the drug discovery process is the identification of high-affinity ligands for macromolecular targets. Traditionally, the identification of such lead compounds has been accomplished through the high-throughout screening (HTS) of corporate compound repositories. Conventional HTS methodology has enjoyed widespread application and success in the pharmaceutical industry and, through recent technological advances in screening (Fernandes, 1998; Oldenburg et al. 1998; Silverman et al. 1998) and combinatorial chemistry (Fauchere et al. 1998; Fecik et al. 1998), these programs will continue to have a prominent role in drug discovery. However, suitable leads cannot always be found using conventional methods. This is not surprising since typical corporate libraries contain fewer than 10 6 compounds compared with the estimated 10 50–10 80 universe of compounds (Martin, 1997). In addition, most conventional assays are limited to screening libraries of compounds against proteins with known function, excluding the large number of targets becoming available from genomics research. Recently, a number of NMR-based screening methods have been employed to identify and design lead ligands for protein targets (see Table 1). These NMR-based strategies can augment ongoing conventional HTS for identifying leads and can be used to aid in lead optimization. All of these techniques take advantage of the fact that upon complex formation between a target molecule and a ligand, significant perturbations can be observed in NMR-sensitive parameters of either the target or the ligand. These perturbations can be used qualitatively to detect ligand binding or quantitatively to assess the strength of the binding interaction. In addition, some of the techniques allow the identification of the ligand binding site or which part of the ligand is responsible for interacting with the target. In this article, the current state of NMR-based screening is reviewed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033583500003528

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 229

Metadata

Authors
Hajduk, P. J., Meadows, R. P., & Fesik, S. W.
Venue
Quarterly Reviews of Biophysics
Published
1999-08
Volume
32
Issue
3
Pages
211-240
ISSN
  • 0033-5835 (ISSN-L)
  • 1469-8994
OpenAlex
W2127375496
Cited by
229
References
2
FWCI
5.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NMR-based screening in drug discovery. https://app.cochat.ai/papers/10.1017/s0033583500003528
The paper
Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1999). NMR-based screening in drug discovery. Quarterly Reviews of Biophysics. https://doi.org/10.1017/s0033583500003528

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.